We are proudly backed by a strong group of global investors focused on improving healthcare outcomes and giving sponsors a better CRO choice.

Best in class

Our best-in-class global institutional investment partners, including a leading US university and a leading global asset manager, support our unique vision and endorse our competitive differentiation, helping us on our mission to reach patients and improve lives.

Qiming Venture Partners
Vivo Capital
Lilly Asia
Springhill Fund
Rock Springs Capital
Kaiser Permanente
Legend Capital
E Fund
Superstring Capital Management LP

Caidya is the trade name of dMedClinical Co. Ltd. and its holdings. Clinipace, Inc. is one company in the Caidya group of companies. Clinipace, Inc. is owned, operated, managed, and controlled by dMedClinical Co. Ltd., a privately held company, whose investors include entities located in the People’s Republic of China (PRC), and which may be subject to PRC laws and regulations that differ from those of the United States. dMedClinical’s investor group are part of a best-in-class shareholder group which includes leading global venture capital and healthcare specialists.

Gateway to the globe

Speak to a global expert

Ready to elevate your clinical development experience? Learn more about how our personalized solutions can help you enable better healthcare outcomes.

Schedule a 15 minute call
Leading a new way

The latest from Caidya

Explore our news and updates as we liberate the clinical research process.


Caidya Achieves Medidata Rave TSDV Accreditation, Enhancing Clinical Trial Efficiency and Data Integrity

Raleigh, N.C., June 12, 2024 – Caidya, a leading provider...


Caidya Expands Global Presence with the Establishment of Caidya Canada Limited and New Office in Toronto

Morrisville, NC, USA, April 1, 2024 - Caidya, a leading...

Gene Therapy Development 2024

13th June 2024 to 14th June 2024
London, UK
Skip to toolbar